WHO approves China’s Sinovac vaccine

The World Health Organization (WHO) has approved the emergency use of a COVID-19 vaccine developed by China’s Sinovac Biotech.
On June 1, the World Health Organization (WHO) approved the emergency use of the COVID-19 vaccine produced by Sinovac Biotech, paving the way for a second Chinese vaccine that can be used in other countries. poor.

The WHO Independent Panel of Experts recommends the use of Sinovac vaccine for people over 18 years of age. The evaluation data show that this vaccine is effective in protection in the elderly. Sinovac is the second Chinese vaccine approved by WHO for emergency use. (Photo: Reuters) WHO’s decision was made based on a review of the latest clinical data on the safety and efficacy of Sinovac’s vaccine as well as the company’s manufacturing practices. On May 5, the WHO technical advisory group met, reviewed and evaluated the Sinovac vaccine. WHO Director-General Tedros Adhanom Ghebreyesus said that Sinovac vaccine is safe and effective, emphasizing that it does not require a high level of vaccine preservation, suitable for low-income countries. “Now it’s important to get these life-saving tools quickly into the hands of those who need them.” , the head of WHO said. Sinovac is the second Chinese vaccine approved by WHO for emergency use. On May 7, the Sinopharm vaccine became the first vaccine not from a Western pharmaceutical company to be approved by the WHO. Meanwhile, China’s third vaccine, manufactured by CanSino Biologics, has also submitted clinical trial data. However, WHO has not yet scheduled an assessment. As of the end of May, Sinovac pharmaceutical company has supplied more than 600 million doses inside and outside China, of which more than 430 million doses have been used.